

## Clinical Policy: Copanlisib (Aliqopa)

Reference Number: ERX.SPA.262

Effective Date: 12.01.18

Last Review Date: 11.21

Line of Business: Commercial, Medicaid

[Revision Log](#)

See **Important Reminder** at the end of this policy for important regulatory and legal information.

### Description

Copanlisib (Aliqopa™) is a phosphatidylinositol-3-kinase inhibitor.

### FDA Approved Indication(s)

Aliqopa is indicated for the treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies.\*

*\*Accelerated approval was granted for this indication based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.*

### Policy/Criteria

*Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.*

*Health plan approved formularies should be reviewed for all coverage determinations. Requirements to use preferred alternative agents apply only when such requirements align with the health plan approved formulary.*

It is the policy of health plans affiliated with Envolve Pharmacy Solutions™ that Aliqopa is **medically necessary** when the following criteria are met:

#### I. Initial Approval Criteria

##### A. Follicular and Other B-Cell Lymphomas (must meet all):

1. Diagnosis of one of the following B-cell lymphoma subtypes (a or b):
  - a. FL;
  - b. Marginal zone lymphoma (off-label) (i, ii, or iii):
    - i. Splenic marginal zone lymphoma;
    - ii. Nodal marginal zone lymphoma;
    - iii. Extranodal marginal zone lymphoma (a or b):
      - a) Gastric MALT lymphoma;
      - b) Nongastric MALT lymphoma;
2. Prescribed by or in consultation with an oncologist or hematologist;
3. Age ≥ 18 years;
4. Relapsed/refractory disease after ≥ 2 prior therapies (see Appendix B for examples);  
*\*Prior authorization may be required*
5. Request meets one of the following (a or b):\*
  - a. Dose does not exceed 60 mg (1 vial) per week for 3 of 4 weeks;
  - b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

*\*Prescribed regimen must be FDA-approved or recommended by NCCN.*

**Approval duration: 6 months**

##### B. Other diagnoses/indications

1. Refer to ERX.PA.01 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized).

#### II. Continued Therapy

##### A. Follicular and Other B-Cell Lymphomas (must meet all):

1. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions, or documentation supports that member is currently receiving Aliqopa for a covered indication and has received this medication for at least 30 days;
2. Member is responding positively to therapy;
3. If request is for a dose increase, request meets one of the following (a or b):\*
  - a. New dose does not exceed 60 mg (1 vial) per week for 3 out of 4 weeks;
  - b. New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

\*Prescribed regimen must be FDA-approved or recommended by NCCN.

**Approval duration: 12 months**

**B. Other diagnoses/indications** (must meet 1 or 2):

1. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions and documentation supports positive response to therapy.

**Approval duration: Duration of request or 6 months (whichever is less);** or

2. Refer to ERX.PA.01 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized).

**III. Diagnoses/Indications for which coverage is NOT authorized:**

- A.** Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off-label use policy – ERX.PA.01 or evidence of coverage documents.

**IV. Appendices/General Information**

*Appendix A: Abbreviation/Acronym Key*

FDA: Food and Drug Administration

FL: follicular lymphoma

NCCN: National Comprehensive Cancer Center

*Appendix B: Therapeutic Alternatives*

*This table provides a listing of preferred alternative therapy recommended in the approval criteria.*

*The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.*

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
<p><b>Follicular Lymphoma</b> <i>Examples of first-line, second-line and subsequent therapies:</i></p> <ul style="list-style-type: none"> <li>• bendamustine + Gazyva® (obinutuzumab) or rituximab</li> <li>• CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) + Gazyva or rituximab</li> <li>• CVP (cyclophosphamide, vincristine, prednisone) + Gazyva or rituximab</li> <li>• <u>Single-agent examples:</u> rituximab; Revlimid® (lenalidomide) ± rituximab</li> </ul>	Varies	Varies
<p><b>Marginal Zone Lymphomas</b> <i>Examples of first-line, second-line and subsequent therapies:</i></p> <ul style="list-style-type: none"> <li>• bendamustine + rituximab, bendamustine + Gazyva®</li> <li>• RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)</li> <li>• RCVP (rituximab, cyclophosphamide, vincristine, prednisone)</li> <li>• <u>Single-agent examples:</u> rituximab; Leukeran® (chlorambucil) ± rituximab; cyclophosphamide ± rituximab; Imbruvica® (ibrutinib); Revlimid ± rituximab; Copiktra® (duvelisib); Zydelig® (idelalisib)</li> </ul>	Varies	Varies

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

*Appendix C: Contraindications/Boxed Warnings*  
None reported

**V. Dosage and Administration**

Indication	Dosing Regimen	Maximum Dose
FL	60 mg IV on Days 1, 8, and 15 of a 28-day treatment cycle on an intermittent schedule (3 weeks on/1 week off)	60 mg/dose/week

**VI. Product Availability**

Single-dose vial: 60 mg

**VII. References**

1. Aliqopa Prescribing Information. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; May 2021. Available at: [www.aliqopa.com](http://www.aliqopa.com). Accessed August 6, 2021.
2. National Comprehensive Cancer Network Drugs and Biologics Compendium. Available at [www.nccn.org](http://www.nccn.org). Accessed August 6, 2021.
3. National Comprehensive Cancer Network. B-Cell Lymphomas Version 4.2021. Available at: [https://www.nccn.org/professionals/physician\\_gls/pdf/b-cell.pdf](https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf). Accessed August 6, 2021.

Reviews, Revisions, and Approvals	Date	P&T Approval Date
Policy created	08.07.18	11.18
4Q 2019 annual review: NCCN recommended B-cell lymphoma subtypes added- Appendix B required therapy examples expanded accordingly; relapsed or refractory disease added; dosing detail - 3 out of 4 weeks - added per PI; FDA/NCCN dosing limitation added; references reviewed and updated.	08.27.19	11.19
4Q 2020 annual review: no significant changes; references reviewed and updated.	07.13.20	11.20
4Q 2021 annual review: no significant changes; references reviewed and updated.	08.06.21	11.21

**Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information.

This Clinical Policy is not intended to dictate to providers how to practice medicine, nor does it constitute a contract or guarantee regarding payment or results. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members.

This policy is the property of Envolve Pharmacy Solutions. Unauthorized copying, use, and distribution of this Policy or any information contained herein is strictly prohibited. By accessing this policy, you agree to be bound by the foregoing terms and conditions, in addition to the Site Use Agreement for Health Plans associated with Envolve Pharmacy Solutions.

©2018 Envolve Pharmacy Solutions. All rights reserved. All materials are exclusively owned by Envolve Pharmacy Solutions and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Envolve Pharmacy Solutions. You may not alter or remove any trademark, copyright or other notice contained herein.